Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenpep for Adjuvant Chemotherapy Completion in Pancreatic Cancer
NCT03469258Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2018
- Primary completion
- Oct 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pancreatin in pancreatic exocrine insufficiency (EPI), sponsored by Dana-Farber Cancer Institute. Started Apr 2018; status: terminated.
02
Drugs
pancreatin
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT03469258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469258.